Paris, April 25, 2019 – Eurazeo Capital announces the completion of the acquisition of DORC (Dutch
Ophthalmic Research Center), one of the global leading specialists of vitreoretinal surgery. Headquartered
in the Netherlands, DORC designs, manufactures and distributes ophthalmic surgery equipment,
consumables and instruments worldwide. DORC enjoys strong market positions notably in Western
Europe, and more recently in the US.
DORC has a strong brand recognition and is widely recognized for its innovation track record. It has
delivered a consistently strong financial performance, supported by growing global ophthalmic surgery
needs.

In 2018, DORC generated revenues of €125 million, with an average annual growth rate of 9% over the
past 3 years. The transaction consists in the acquisition of 100% of the share capital of DORC and will be
the fifth investment of Eurazeo Capital IV. The company is valued at c. €430 million (enterprise value), of
which c. €300 million equity funded by Eurazeo and its affiliates.

About Eurazeo
o Eurazeo is a leading global investment company, with a diversified portfolio of €17 billion in assets under
management, including nearly €11 billion from third parties, invested in over 300 companies. With its considerable
private equity, venture capital, real estate, private debt and fund of funds expertise, Eurazeo accompanies companies
of all sizes, supporting their development through the commitment of its 235 professionals and by offering deep sector
expertise, a gateway to global markets, and a responsible and stable foothold for transformational growth. Its solid
institutional and family shareholder base, robust financial structure free of structural debt, and flexible investment
horizon enable Eurazeo to support its companies over the long term.
Eurazeo has offices in Paris, New York, Sao Paulo, Buenos Aires, Shanghai, London, Luxembourg, Frankfurt and
Madrid.
o Eurazeo is listed on Euronext Paris.
o ISIN: FR0000121121 – Bloomberg: RF FP – Reuters: EURA.PA